References
- CzernichowSZanchettiATurnbullFThe effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trialsJ Hypertens20112941620881867
- ConroyRMPyöräläKFitzgeraldAPEstimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE projectEur Heart J200324987100312788299
- De BackerGPetrellaJRGoudevARDesign and methodology of POWER, an open-label observation of the effect of primary care interventions on total cardiovascular risk in patients with hypertensionFundam Clin Pharmacol1142011 [Epub ahead of print.].
- Blood Pressure Lowering Treatment Trialists’ CollaborationEffects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trialsLancet20033621527153514615107
- AmbrosioniEBombelliMCerasolaGAmbulatory monitoring of systolic hypertension in the elderly: eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST trial)Adv Ther20102736538020556561
- ConterHSMcKayDWReizRJEprosartan mesylate effectively reduces systolic and diastolic blood pressure in a Canadian primary care settingCan J Cardiol200420Suppl C6C10C
- SchraderJLüdersSKulschewskiAMorbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES)Stroke2005361218122615879332
- GuallarEBanegasJRBlasco-ColmenaresEExcess risk attributable to traditional cardiovascular risk factors in clinical practice settings across Europe – The EURIKA StudyBMC Public Health20111170421923932
- XuFYYangBShiDLiHZouZShiXYAntihypertensive effects and safety of eprosartan: a meta-analysis of randomized controlled trialsEur J Clin Pharmacol20126819520521881888
- BöhmMSachseASafety and tolerability of eprosartan in combination with hydrochlorothiazideDrug Saf20022559961112113644
- BaumhäkelMBöhmMCardiovascular outcomes with angiotensin II receptor blockers: clinical implications of recent trialsVasc Health Risk Manag2011739139721796253
- FlackJMNasserSABenefits of once-daily therapies in the treatment of hypertensionVasc Health Risk Manag2011777778722241952
- De BackerGThe SCORE model in the POWER study: an attempt to focus the limited resources for prevention on patients with greatest needCurr Med Res Opin200723Suppl 5S19S2418093410